

Responses to Reviewers of PLoS Biology ms  
PBIOLGY-D-19-02569R2  
“Patterns of smallpox mortality in London, England,  
over three centuries”

Olga Krylova and David Earn

September 2, 2020

1 Dear Roli,

2 Thank you for the second round of reviews of our paper.

3 We have made the requested revisions and respond point-by-point to the reviewers’ comments  
4 below. For convenience, we include below the text of your decision letter and all the reviews.  
5 Our responses are in [blue](#).

6 Sincerely,  
7 David Earn and Olga Krylova

8



9 **EDITOR’S DECISION LETTER:**

10 Date: 10 Aug 2020 09:01:07 -0400

11 Subject: Your PLoS Biology Submission (PBIOLGY-D-19-02569R2) - [EMID:80236b3b94569ef1]

12 Dear Dr Earn,

13 Thank you for submitting your revised Research Article entitled “Patterns of smallpox mor-  
14 tality in London, England, over three centuries” for publication in PLoS Biology. I have

15 now obtained advice from three of the original reviewers and have discussed their comments  
16 with the Academic Editor.

17 Based on the reviews, we will probably accept this manuscript for publication, assuming  
18 that you will modify the manuscript to address the remaining points raised by the reviewers.  
19 IMPORTANT: The article type still seems to be "Short Report"; please change it to "Re-  
20 search Article" when re-submitting. Please also make sure to address the Data Policy-related  
21 requests noted at the end of this email.

22 Roli Roberts e-mailed on 2 Sep 2020 to say that the journal will take care of the change to  
23 "Research Article".

24 We expect to receive your revised manuscript within two weeks. Your revisions should  
25 address the specific points made by each reviewer. In addition to the remaining revisions  
26 and before we will be able to formally accept your manuscript and consider it "in press", we  
27 also need to ensure that your article conforms to our guidelines. A member of our team will  
28 be in touch shortly with a set of requests. As we can't proceed until these requirements are  
29 met, your swift response will help prevent delays to publication.

30 \*Copyediting\*

31 Upon acceptance of your article, your final files will be copyedited and typeset into the final  
32 PDF. While you will have an opportunity to review these files as proofs, PLOS will only  
33 permit corrections to spelling or significant scientific errors. Therefore, please take this final  
34 revision time to assess and make any remaining major changes to your manuscript.

35 NOTE: If Supporting Information files are included with your article, note that these are  
36 not copyedited and will be published as they are submitted. Please ensure that these files  
37 are legible and of high quality (at least 300 dpi) in an easily accessible file format. For  
38 this reason, please be aware that any references listed in an SI file will not be indexed. For  
39 more information, see our Supporting Information guidelines: [https://journals.plos.  
40 org/plosbiology/s/supporting-information](https://journals.plos.org/plosbiology/s/supporting-information)

41 \*Published Peer Review History\*

42 Please note that you may have the opportunity to make the peer review history publicly avail-  
43 able. The record will include editor decision letters (with reviews) and your responses to re-  
44 viewer comments. If eligible, we will contact you to opt in or out. Please see here for more de-  
45 tails: <https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-revie>

46 \*Early Version\*

47 Please note that an uncorrected proof of your manuscript will be published online ahead of  
48 the final version, unless you opted out when submitting your manuscript. If, for any reason,  
49 you do not want an earlier version of your manuscript published online, uncheck the box.  
50 Should you, your institution's press office or the journal office choose to press release your  
51 paper, you will automatically be opted out of early publication. We ask that you notify us  
52 as soon as possible if you or your institution is planning to press release the article.

53 \*Protocols deposition\*

54 To enhance the reproducibility of your results, we recommend that if applicable you deposit  
55 your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier  
56 (DOI) such that it can be cited independently in the future. For instructions see: [https://  
57 journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods](https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods)

58 \*Submitting Your Revision\*

59 To submit your revision, please go to <https://www.editorialmanager.com/pbiology/> and  
60 log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your  
61 submission record. Your revised submission must include a cover letter, a Response to  
62 Reviewers file that provides a detailed response to the reviewers' comments (if applicable),  
63 and a track-changes file indicating any changes that you have made to the manuscript.

64 Please do not hesitate to contact me should you have any questions.

65 Sincerely,

66 Roli Roberts

67 Roland G Roberts, PhD,  
68 Senior Editor,  
69 [rroberts@plos.org](mailto:rroberts@plos.org),  
70 PLOS Biology

71

---

72 DATA POLICY:

73 You may be aware of the PLOS Data Policy, which requires that all data be made available  
74 without restriction: <http://journals.plos.org/plosbiology/s/data-availability>. For  
75 more information, please also see this editorial: [http://dx.doi.org/10.1371/journal.  
76 pbio.1001797](http://dx.doi.org/10.1371/journal.pbio.1001797)

77 We note that your raw data are deposited in <http://iidda.mcmaster.ca> - however, we  
78 strongly prefer more stable, non-institutional repositories (e.g. Dryad, Figshare, Github),  
79 and request that you make such provision for depositing your data and code. At the moment  
80 <http://iidda.mcmaster.ca> is giving a timeout error, which gives us further for the long-  
81 term availability of this important dataset.

82 We understand your concerns and we have created a github repository ([https://github.  
83 com/davidearn/London\\_smallpox](https://github.com/davidearn/London_smallpox)) that includes all the data and all the R scripts that  
84 create our figures. The IIDDA web site should have been functioning by now, but the  
85 COVID-19 pandemic has caused many delays. Our plan is for the URL that times out  
86 for you at the moment to eventually point to a very stable CKAN link. We will therefore  
87 continue to state in the paper that the data are available at IIDDA, as well as at the new  
88 github repo. If you prefer to have the data available, in addition, on the PLoS website as a  
89 supplementary .zip file, please let us know.

90 In addition, we ask that all individual quantitative observations that underlie the data  
91 summarized in the figures and results of your paper be made available in one of the following  
92 forms:

93 1) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Sup-  
94 porting Information' and are invariably referred to (in the manuscript, figure legends, and the  
95 Description field when uploading your files) using the following format verbatim: **S1 Data**,  
96 **S2 Data**, etc. Multiple panels of a single or even several figures can be included as multiple  
97 sheets in one excel file that is saved using exactly the following convention: **S1\_Data.xlsx**  
98 (using an underscore).

99 2) Deposition in a publicly available repository. Please also provide the accession code or a  
100 reviewer link so that we may view your data before publication.

101 See [https://github.com/davidearn/London\\_smallpox](https://github.com/davidearn/London_smallpox).

102 Regardless of the method selected, please ensure that you provide the individual numerical  
103 values that underlie the summary data displayed in the following figure panels as they are  
104 essential for readers to assess your analysis and to reproduce it: Figs 1, 2, 3, 4, 5, 6, S1, S2.  
105 NOTE: the numerical data provided should include all replicates AND the way in which the  
106 plotted mean and errors were derived (it should not present only the mean/average values).

107 Please also ensure that figure legends in your manuscript include information on where the  
108 underlying data can be found, and ensure your supplemental data file/s has a legend.

109 We have added the following statement to the caption for each figure (other than Fig 1,  
110 which is just a photograph). "The data and R script required to reproduce this figure are  
111 available at [https://github.com/davidearn/London\\_smallpox](https://github.com/davidearn/London_smallpox)."

112 Please ensure that your Data Statement in the submission system accurately describes where  
113 your data can be found.

114



115 REVIEWERS' COMMENTS:

116 **Reviewer #2: [identifies herself as Romola Davenport]**

117 The authors have done a great job in revising the paper. It is much clearer and more  
118 tightly written, and presents a very impressive integration of historical and epidemiological  
119 literatures. I think it will make a great addition to current debates over the recent evolution  
120 of smallpox.

121 Thanks very much!

122 I have only minor comments that should be addressed before publication.

123 1. The authors are now perhaps too reticent in attributing causation, especially with re-  
124 spect to vaccination (page 14/33, lines 431-6). The decline in smallpox deaths with the  
125 introduction of vaccination in the early nineteenth century is very marked in both raw and  
126 normalised burials. This phenomenon was observed in other cities and states that adopted  
127 vaccination, and coincided with a marked decline in all-cause mortality (so the reduction in  
128 normalised smallpox burials is likely to underestimate the fall in smallpox mortality).

129 We have revised the sentence in question, which now reads “The declining trend in epidemic  
130 severity is temporally associated with the introduction of vaccination; unfortunately, this  
131 was precisely the period over which the parish registration system collapsed, increasing the  
132 difficulty of estimating the true impact of vaccination in the early vaccine era.”

133 2. The term ‘mortality’ usually refers to mortality \*rates\*, that is, deaths per population at  
134 risk. The authors should distinguish clearly when they are talking about counts of deaths  
135 or normalised deaths, to avoid confusion. Figure 1 top panel should be labelled as smallpox  
136 deaths, not mortality, and the y-axis should read ‘weekly smallpox deaths’. The y-axis of  
137 Figure 2 should also be labelled ‘weekly all-cause deaths’.

138 We have made the suggested changes to the figure labels.

139 3. A slightly larger comment: Why were normalised deaths used to study seasonal pat-  
140 terns? Seasonal patterns in raw deaths should be largely unaffected by longer-term changes  
141 in reporting units or under-registration (for the same reasons that normalised deaths are  
142 preferable for other purposes). The use of raw deaths to study seasonality would avoid the  
143 potential distortions caused by other seasonal patterns of mortality. For example, scarlet  
144 fever emerged as a major cause of death in London in the 1930s, with a marked autumnal  
145 pattern. This could have reduced the proportion of all deaths due to smallpox in the autumn,  
146 regardless of the underlying seasonal pattern of smallpox mortality in this period. Other  
147 important causes of death also showed seasonal patterns, and some of these changed over  
148 the period of the study (including measles). The authors should acknowledge this potential  
149 problem, if they prefer to use normalised burials and deaths.

150 We believe that the referee has mistakenly inferred that we normalized by weekly all-cause  
151 deaths. Had we done so, we would agree that this would interfere with our ability to detect  
152 seasonal patterns in smallpox. Indeed, in the extreme that most deaths were attributed to  
153 smallpox, dividing by all-cause deaths would remove the seasonality altogether.

154 In fact, as we explain in the Normalization subsection of the Methods section, we normal-  
155 ized smallpox deaths by the long term trend in all-cause deaths, which has no seasonality.  
156 Smallpox deaths are therefore scaled conveniently without affecting seasonal patterns.

157 4. Table 1 (appendix B): the labels for the third and fourth columns appear to be transposed.

158 We have re-ordered the columns.

159 5. page 3/33 line 51: another important element in the eradication of smallpox was the

160 relatively low infectivity of smallpox.

161 We have added “relatively low infectivity” to the list.

162 6. page 3/33 line 60: insert ‘and only for a few towns’ between ‘until later’ and ‘Bills of  
163 Mortality’.

164 Done – thanks.

165 7. page 4/33, line 81: perhaps replace ‘exists’ with ‘survives’ (to avoid the impression that  
166 patchy series necessarily imply gaps in the production of weekly bills as opposed to survival).

167 Done – thanks.

168 8. page10/33, line 256-7: perhaps add ‘need for periodic revaccination’ to the list of im-  
169 pediments to vaccine uptake. There was some resurgence of smallpox, and a rise in average  
170 age of victims, in the 1820s and 1830s that may have been associated with the waning of  
171 vaccine-derived immunity in birth cohorts in which vaccination was very common.

172 (The correct line reference is 266–7.)

173 Done – thanks. We have said “waning immunity (hence a need for periodic revaccination)”.

174 9. Typographical errors: abstract line 1, ‘devastated’ for ‘devasted’; page 14/33, line 427:  
175 ‘and’ for ‘an’; page 14/35, line 434: insert ‘of’ after ‘introduction’.

176 Repaired – thanks for catching these.

### 177 **Reviewer #3:**

178 I appreciate the revisions that went into this manuscript, and I think it is very close to  
179 publication-ready at PLoS Biology. I remain convinced that the data, by itself, is incredibly  
180 valuable, and the extended analysis presented here makes this paper a more meaningful  
181 contribution as well. I have only a few comments that should be straightforward to address.

182 I feel that the importance (the “so what” question) of the analyses presented here needs  
183 to be better articulated in the Introduction and Discussion sections. Right now the value  
184 is implicit throughout the manuscript, and nowhere do the authors state clearly what they  
185 can learn from the statistical analysis of this data, and how will what they learn from these  
186 analyses be useful, both for understanding infectious diseases more generally and also for  
187 the next phase of work on smallpox specifically (e.g., building mechanistic models).

188 The end of the Introduction now reads:

189 Our statistical descriptions of the weekly smallpox data will help sharpen and  
190 quantify research questions concerning the mechanistic origin of changes in the  
191 temporal patterns of epidemics [11-14]. In addition, we present a timeline of ma-

192 jor historical events that occurred during the epoch we have studied. Overlaying  
193 the historical timeline with smallpox mortality and prevention patterns provides  
194 an illuminating view of three centuries of smallpox history.

195 In the Discussion, we have added this sentence in the subsection "Explaining transitions in  
196 smallpox dynamics":

197 Our spectral and seasonal analyses (Figs 5-7) quantify transitions in smallpox  
198 dynamics that should be possible to explain using mechanistic mathematical  
199 models.

200 On the description of the handling of the heaped data, you might note that you considered  
201 other ways of handling the heaped data (e.g., the way it was handled in the first version of  
202 the manuscript) and that this did not have any effect on the conclusions drawn here.

203 The final bullet point in the description of heaping now reads:

204 We calculated the difference between original heaped count and the replaced  
205 value (the "excess" due to heaping), and redistributed this number of smallpox  
206 deaths in proportion to reported smallpox throughout the year (so the adjusted  
207 counts have non-integer values). This redistribution ensured that the original and  
208 revised time series contained the same annual numbers of smallpox deaths. (We  
209 separately considered redistributing the excess uniformly throughout the year,  
210 and did not detect any differences in our results.)

211 The rationale for identifying the "Intervention uptake levels" in Fig. 1 is never made clear.  
212 Why, for example, does the assumed uptake level go from "very low" to "low" in 1728? Why  
213 does it go from "low" to "moderate" in 1740, if the first charitable variolation hospital didn't  
214 open until 1746? Etc. I realize that this doesn't impact the analyses presented here (because  
215 you are not seeking to draw any quantitative conclusions between the dynamics and the level  
216 of intervention uptake), but I still think it would be useful to provide some justification.

217 As we now clarify in the paper, we assume that the level during the period 1728–1740 was  
218 between the known very low level before 1728 and the known higher level after 1740. We now  
219 provide several references to support our indication of an increase to "Moderate" variolation  
220 uptake levels around 1740. For example, Tucker (2002) states "variolation became popular in  
221 England by the 1740s". The changes after 1768 are supported by the Razell references that  
222 we cite in the main text when referring to the period of increase in popularity of variolation.  
223 To emphasize that we are doing the best we can with qualitative information, we now state:

224 From these qualitative descriptions, it seems likely that uptake of variolation  
225 increased after 1768 and reached a maximum during 1790–1808 [3,61] (annotated  
226 in Fig 3).

227 You do not justify the use of square-root transformation in the spectral analysis section.  
228 Also, in this section it would be useful to explain to a reader who has limited exposure to  
229 time series analysis what is gained by carrying out both the power spectrum analysis and  
230 the wavelet analysis.

231 We have expanded the introductory paragraph in the “Spectral analysis” section, which now  
232 reads:

233 We used spectral analyses to identify the strongest periodicities in the smallpox  
234 time series, both globally (with a traditional Fourier analysis) and locally (via  
235 wavelet analysis). Before computing spectra, we normalized and square-root  
236 transformed the data in order to reduce variation in amplitude without affecting  
237 periodicities [74,75].

238 You are missing an ”of” on line 434 between ”introduction” and ”vaccination.”

239 Done – thanks – also mentioned by Reviewer #2.

240 There is some inconsistency in how Fig. 4B is discussed in the Results and Discussion. In  
241 the Results, the power of the annual period is not discussed - you only mention periods at 2,  
242 3, and 5 years. But in the Discussion (lines 465-466), you say that ”the wavelet spectrum in  
243 Fig. 4B shows a peak at one year,” a finding that is not very apparent in Fig. 4B (at least  
244 to me).

245 Thank you. Not mentioning the one-year period in the Results was an oversight. We have  
246 added the following sentence in the Results:

247 A relatively weak spectral peak at one year can be seen over much of the time  
248 series before 1820, though its magnitude is below the threshold for drawing a  
249 black peak line except for the decade 1798–1808.

250 The discussion of possible viral evolution (lines 551-559) could reference some of the theoret-  
251 ical work by Sylvain Gandon and Troy Day on how vaccination is expected to drive pathogen  
252 evolution (especially the reference on line 557-559 that suggests the potential for variolation  
253 to be ”leaky”). E.g., Gandon, S., Mackinnon, M. J., Nee, S., & Read, A. F. (2001). Imper-  
254 fect vaccines and the evolution of pathogen virulence. *Nature*, 414(6865), 751-756. Gandon,  
255 S., & Day, T. (2007). The evolutionary epidemiology of vaccination. *Journal of the Royal  
256 Society Interface*, 4(16), 803-817.

257 Thanks – we have now cited these papers.

258 To help foreshadow the future work you anticipate in response to these data and analyses,  
259 you might say a bit more about \*how\* the studies of measles and other childhood infections  
260 were able to explain dynamical transitions evident in the data (lines 583-588).

261 This comment refers to the “Explaining transitions in smallpox dynamics” section in the  
262 Discussion. The paragraph immediately following the cited lines addresses this, and we



263 are not sure what additional commentary the referee was hoping for. We have added the  
264 following sentence at the end of the paragraph in question:

265 Our spectral and seasonal analyses (Figs 5–7) quantify transitions in smallpox  
266 dynamics that should be possible to explain using mechanistic mathematical  
267 models [64,78,97,98].

268 You are missing an "in" on line 610 between "patterns" and "infectious."

269 Repaired – thanks for catching this.

#### 270 **Reviewer #4:**

271 The authors have done a great job at clarifying my questions and addressing my concerns in  
272 the revision. The revised presentation on the changes in seasonality and on the interannual  
273 variation is now very clear. I also appreciated the discussion on the directions these data  
274 and patterns open up for future research.

275 Thank you!

276

277 In compliance with data protection regulations, you may request that we remove your per-  
278 sonal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/pbiology/login.asp?a=r>). Please contact the publication office if you have any ques-  
279 tions.  
280